Answers are grounded in this paper and cite their sources.
Background/Objectives: Carbapenems remain the standard treatment for infections caused by extended-spectrum β-lactamase–producing Enterobacterales (ESBL-E), but their widespread use contributes to the emergence of carbapenem resistance. Cephamycins have been proposed as carbapenem-sparing alternatives because of their relative stability against ESBL-mediated hydrolysis; however, their clinical effectiveness remains uncertain. We aimed to compare the effectiveness of cephamycins versus carbapenems as definitive treatment for ESBL-E infections. Methods: We searched Scopus, PubMed, and Embase for studies comparing cephamycins with carbapenems for the treatment of ESBL-producing Enterobacterales infections, with the search conducted through January 2026. Observational studies and randomized trials comparing cephamycins (cefmetazole, flomoxef, cefoxitin) with carbapenems in adult patients with microbiologically confirmed ESBL-E infections were included. The primary outcome was all-cause mortality; secondary outcomes were clinical and microbiological cure. Risk of bias was assessed using ROBINS-I, and data were pooled using random-effects models. Results: Ten retrospective cohort studies (n = 653 for mortality) were included. Cephamycins were associated with a non-significant trend toward lower mortality compared with carbapenems (OR 0.48, 95% CI 0.22–1.03). Subgroup analyses suggested a potential benefit in Escherichia coli and urinary-source infections, whereas no advantage was observed in Klebsiella pneumoniae or non-urinary bloodstream infections. No significant differences were found for clinical or microbiological cure. The certainty of evidence was rated as very low. Conclusions: Cephamycins may represent a carbapenem-sparing option in carefully selected patients with low-risk ESBL-E infections, particularly urinary-source infections caused by E. coli. However, the current evidence is limited to retrospective observational studies with very low certainty and should be considered hypothesis-generating rather than practice-changing. Adequately powered randomized controlled trials are needed to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Franceschi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: